Gilead Sciences, Inc. (ETR:GIS)
106.54
-0.24 (-0.22%)
Nov 6, 2025, 5:35 PM CET
Gilead Sciences Revenue
Gilead Sciences had revenue of $7.77B USD in the quarter ending September 30, 2025, with 2.97% growth. This brings the company's revenue in the last twelve months to $29.09B, up 2.78% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$29.09B
Revenue Growth
+2.78%
P/S Ratio
5.36
Revenue / Employee
$1.65M
Employees
17,600
Market Cap
132.85B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
| Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
| Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
| Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
| Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 46.17B |
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.45B |
| Merck KGaA | 21.22B |
| Fresenius Medical Care AG | 19.64B |
| Sartorius Aktiengesellschaft | 3.52B |
| Redcare Pharmacy NV | 2.82B |
| Fielmann Group AG | 2.40B |
Gilead Sciences News
- 2 days ago - Kymera outlines mid-2027 topline readout for KT-621 Phase IIb study as pipeline advances and Gilead partnership grows - Seeking Alpha
- 2 days ago - Gilead Sciences to Present at Upcoming Investor Conferences - Business Wire
- 2 days ago - See Which Of The Latest 13F Filers Holds GILD - Nasdaq
- 2 days ago - HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline - Nasdaq
- 2 days ago - Fernandez: The market is on a high wire right now - CNBC
- 3 days ago - Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025 - Business Wire
- 3 days ago - Kalaris appoints Matthew Gall as CFO - Seeking Alpha
- 6 days ago - Needham Reiterates Gilead Sciences (GILD) Buy Recommendation - Nasdaq